Polycystic ovary syndrome (PCOS) is the most common female endocrinopathy associated with both reproductive and metabolic disorders. Dehydroepiandrosterone (DHEA) is currently used to induce a PCOS mouse model. High-fat diet (HFD) has been shown to cause obesity and infertility in female mice. The possible effect of an HFD on the phenotype of DHEAinduced PCOS mice is unknown. The aim of the present study was to investigate both reproductive and metabolic features of DHEA-induced PCOS mice fed a normal chow or a 60% HFD. Prepubertal C57BL/6 mice (age 25 days) on the normal chow or an HFD were injected (s.c.) daily with the vehicle sesame oil or DHEA for 20 consecutive days. At the end of the experiment, both reproductive and metabolic characteristics were assessed. Our data show that an HFD did not affect the reproductive phenotype of DHEA-treated mice. The treatment of HFD, however, caused significant metabolic alterations in DHEAtreated mice, including obesity, glucose intolerance, dyslipidemia, and pronounced liver steatosis. These findings suggest that HFD induces distinct metabolic features in DHEA-induced PCOS mice. The combined DHEA and HFD treatment may thus serve as a means of studying the mechanisms involved in metabolic derangements of this syndrome, particularly in the high prevalence of hepatic steatosis in women with PCOS.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy and one of the most frequent causes of infertility in women of reproductive age. It is a heterogeneous syndrome with the characteristics of hirsutism, acne, anovulation, hyperandrogenemia, and polycystic ovaries [1, 2] . In most cases, PCOS also involves metabolic abnormalities, including obesity, dyslipidemia, and insulin resistance (IR) [3, 4] . Recently, it has been shown that women with PCOS have hypertrophic adipocytes [5] , increased amounts of visceral adipose tissue [6] , and a higher prevalence of hepatic steatosis [7] than age-and weight-matched healthy controls. Polycystic ovary syndrome is thus now recognized as an important metabolic disorder as well as reproductive morbidity.
Although PCOS was described almost 80 yr ago, the etiology of PCOS still remains unclear. The heterogeneity of the clinical and biochemical features of PCOS makes its treatment even more challenging. To gain a better understanding of the pathogenesis of PCOS, it is important to have a suitable animal model that replicates many or most reproductive and metabolic features of this syndrome. Dehydroepiandrosterone (DHEA) has been widely used to generate PCOS animal models in mice and rats [8] [9] [10] [11] [12] [13] . The DHEA-treated mice exhibit some human PCOS characteristics, including acyclicity, anovulation, polycystic ovaries, and hyperandrogenism [13, 14] . In addition, these mice display IR in the BALB/c strain [10] and impaired glucose tolerance in the C57B/6 strain [13] . Limited data, however, were present pertaining to other metabolic characteristics of this model, particularly features of the liver, adipose tissue, and skeletal muscle. It has been reported that female mice with high-fat diet (HFD)-induced obesity exhibit infertility, and HFD-treated mice can serve as an animal model for PCOS [15] . We thus speculated whether the combined treatment of DHEA and HFD can affect both reproductive and metabolic phenotype of the mice. Moreover, Dowling et al. [13] have compared DHEA-induced PCOS mouse models in the BALB/c and C57B/6 strains and suggested that the C57BL/6 strain provides a better experimental platform for PCOS research. The C57BL/6 mice were thus chosen in the present work. Therefore, prepubertal female C57BL/6 mice were administered with DHEA and fed a normal chow or a 60% HFD in the current study. At the end of the experiment, both reproductive and metabolic features of the mice were evaluated.
MATERIALS AND METHODS

Animals and Experimental Protocols
Female C57BL/6 mice (age 21 days) were purchased from the animal facility of the Peking University Health Science Center. All animals were bred, housed locally at 228C 6 28C, and were acclimated to standard laboratory conditions (12L:12D cycle) with free access to rodent feed and water. At Postnatal Day 25, the mice of comparable weights ranging from 7.3 to 10.3 g were randomly divided into four groups (n ¼ 8 per group). Group 1: control group. The mice were fed a normal chow and injected (s.c.) daily with sesame oil (0.1 ml per 100 g body weight). Group 2: HFD group. Mice were fed an HFD (60% of calories from fat; Research Diets) and injected (s.c.) daily with sesame oil (0.1 ml per 100 g body weight). Group 3: DHEA group. Mice were fed a normal chow and injected (s.c.) daily with DHEA (6 mg per 100 g body weight) dissolved in 0.1 ml of sesame oil. Group 4: DHEA þ HFD group. The mice were fed an HFD and injected (s.c.) daily with DHEA. After 20 days of the treatments, both reproductive and metabolic features were evaluated. The treatments were continued until the mice were killed. All animal protocols were approved by the Animal Care and Use Review Committee of Peking University Health Science Center in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Estrous Cycle Determination
The estrous cycle was determined daily 13 days after the injection (Day 38 of life) and assessed for 7 consecutive days. Vaginal cells were collected via saline lavage and then fixed with methanol and stained with methylene blue staining (0.1%). The stages of the estrous cycle were determined based on vaginal cytology: predominant nucleated epithelial cells indicated the proestrus stage, predominant cornified squamous epithelial cells indicated the estrus stage, both cornified squamous epithelial cells and leukocytes indicated the metaestrus stage, and predominant leukocytes indicated the diestrus stage.
Oral Glucose Tolerance Test
Oral glucose tolerance test (OGTT) was performed right after 20 days of the treatment (Day 46 of life). The mice were fasted for 6 h before administration of glucose (3 g/kg body weight per 3 ml) by oral gavage. Blood samples were collected from the tail vein for the measurements of blood glucose levels immediately before glucose administration and then at 30, 60, 90, and 120 min after administration with the OneTouch Ultra glucometer (Accu-Check Sensor; Roche Diagnostics). Data were expressed as the absolute values of blood glucose concentrations. Total area under the curve of the glucose response (AUC) was calculated using GraphPad Prism 5.0 software.
Insulin Tolerance Test
Five days after the OGTT experiment, an insulin tolerance test (ITT) was carried out (Day 51 of life). The mice were fasted for 6 h and then injected intraperitoneally with insulin (1 IU/kg body weight). Blood glucose was measured immediately before insulin administration and then at 30, 60, 90, and 120 min after injection. Data were expressed as the values of blood glucose concentrations corrected for fasting glucose. Total AUC of the corrected glucose values was calculated using GraphPad Prism 5.0 software.
Body Composition Analysis
Body composition analysis was performed 1 day after ITT experiment (Day 52 of life). The mice were placed in a clear plastic holder without anesthesia or sedation and inserted into the EchoMRI device (Echo Medical Systems) to measure total body fat and lean mass.
Tissue Collection and Histology
After body composition analysis, the mice were housed for 1 day. Then the mice were anesthetized via an intraperitoneal injection of a mixture of ketamine hydrochloride and xylazine (Day 53 of life). Blood samples were collected from inferior vena cava. Ovary and liver samples were then rapidly removed from the animals. One ovary from each mouse and a piece of liver sample were fixed in 4% paraformaldehyde (PFA) and postfixed in 20% sucrose solution. Afterward, tissues were embedded into Tissue-Tek (O.C.T. compound; Sakura), frozen at À808C overnight, and cut into sections (6-lm thickness) with a Leica Cryostat (LEICA CM1850). The remaining liver samples were snap frozen in liquid nitrogen and then kept at À808C for protein and RNA extraction, and the measurement of hepatic lipid contents. Intra-abdominal fat samples (ovarian and retroperitoneal fat pads) were dissected, weighed, and fixed overnight in 4% PFA at 48C and embedded in paraffin. Skeletal muscles from the hind limbs (quadriceps muscle) were dissected, snap frozen in liquid nitrogen, and then kept at À808C for protein assay. Fat (5-lm thickness), ovary, and liver sections were stained with hematoxylin and eosin (H&E) according to the standard histological procedures. To examine ovarian morphology, every 12th section was mounted on a glass slide. Numbers of corpora lutea and large antral follicles were counted. A cystic follicle is considered to be a large fluidfilled cyst with an attenuated granulosa cell layer and thickened theca cell layer [16] . The count of large antral follicles was performed based on the mean diameter of the follicles greater than 311 lm. The area of the largest follicles was measured with ImageJ (National Institutes of Health) software.
Measurement of Serum Sex Steroids
Serum testosterone levels were determined with 125 I-labeled radioimmunoassay kits (Beijing North Institute of Biological Technology). The withinassay and between-assay variabilities were 10% and 15%, respectively.
Measurement of Serum and Hepatic Triglyceride and Cholesterol Contents
Lipids from the livers were extracted with Folch solution consisting of a mixture of 2:1 (vol/vol) chloroform and methanol. Lipids were then solubilized in 5% Triton X-100 after evaporation under nitrogen gas. Serum and hepatic triglyceride (TG) and cholesterol levels were determined with commercially available kits (BIOSINO Bio-Technology and Science Inc.) according to the manufacturer's instructions.
Real-Time PCR
Total RNA was extracted by using TRIzol (Invitrogen). Aliquots of 2 lg of total RNA from each sample were reverse transcribed to cDNA. Primer sequences (Table 1) were either previously published sequences [17] [18] [19] [20] [21] or designed using Primer 3 software. Real-time PCR was performed using fluorescent SYBR Green according to the manufacturer's instructions (Invitrogen). b-Actin was used as an internal standard. The amplified products were verified by agarose gel electrophoresis and melting curves. The expression of the target genes was normalized to that of b-actin in the same sample using the 2
ÀDCt method. Each sample was measured in duplicate in each experiment.
Western Blot Analysis
Western blot analysis was performed as described previously [22] . In brief, aliquots of 10 lg of protein of each sample were separated by SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked and subsequently probed with primary antibodies at 48C overnight. Antibodies to phosphorylated Akt (p-AKT) at serine 473 (1:1000; CST no. 4060L) and total AKT (1:1000; CST no. 9272) were purchased from Cell Signaling Technology. The antibody to EIF-5 (1:2000) was bought from Santa Cruz Biotechnology (no. K1607). EIF-5 was used as an internal control. The membrane was washed and then incubated with a horseradish peroxide-conjugated secondary antibody. After washing, the membrane was developed with ECL Reagent (Vigorous Biotechnology) and exposed to Kodak XBT-1 film. Densitometric analysis was performed, and protein expression level was quantified with Image J software.
Immunohistochemistry
Immunohistochemistry was performed as described previously [23] . In brief, fat sections (5-lm thickness) were deparaffinized and washed. Endogenous peroxidase activity was quenched with 3% (vol/vol) H 2 O 2 in methanol. Antigen retrieval was performed by heating sections in 10 mM citrate buffer. Tissue sections were then blocked with 1% bovine serum albumin for 20 min at 378C, followed by overnight incubation at 48C with the mouse anti-F4/80 antibody (1:200; ABD Serotec). Nonimmune immunoglobulin G (IgG) was used as the negative control. Sections were then incubated with a polyperoxidase-conjugated rabbit anti-mouse IgG (Zhongshan Golden Bridge) for 20 min at 378C. Immunostaining was revealed by using diaminobenzidine and counterstained with hematoxylin. Immunostaining intensity was evaluated by three independent observers not involved with the study who were asked to rate the intensity of the staining without knowing the identity of samples.
Oil Red O Staining
Frozen liver sections were stained with Oil Red O to detect neutral lipid accumulation according to the standard procedure. Briefly, sections were fixed at room temperature in 4% PFA, washed with distilled water, and then washed with 70% isopropanol before incubation with Oil Red O. Slides were then counterstained with hematoxylin and coverslipped with a water-based mounting medium.
Measurement of Adipocyte Size
Fat sections were stained with H&E. Three mice per group were randomly selected. Micrographs were taken at 4003 magnification. In three randomly selected micrographs per section, the diameter of adipocytes was measured using ImageJ software, and then the number of adipocytes falling into each field with intervals of 5 lm was counted.
Statistical Analysis
Data are presented as mean 6 SEM. Statistical analyses were performed with GraphPad Prism 5.0 software. Effects of the treatments were first analyzed by two-way analysis of variance (ANOVA) with HFD and DHEA as the fixed variables. The one-way ANOVA was then performed followed by Bonferroni posttest. P , 0.05 was considered statistically significant.
RESULTS
Estrous Cyclicity and Ovary Morphology
Menstrual disturbance is a typical clinical feature of PCOS women. All of the control mice had a normal estrous cyclicity. In contrast, HFD mice exhibited a cycle length exceeding 7 or more days, and all the mice treated with DHEA or DHEA þ HFD displayed disrupted estrous cycles (Fig. 1A) . Weight of the ovaries did not differ among the four groups of mice (data not shown). Representative micrographs of ovarian sections are shown in Figure 1B . No cystic follicles were observed in control or HFD mice. In contrast, the number of such follicles was remarkable in DHEA and DHEA þ HFD mice. About 67% of DHEA-treated mice contained a cystlike appearance of follicles in the ovaries; 85% of DHEA þ HFD mice exhibited such structures (Fig. 1B) . But there was no significant difference in ovarian morphology between DHEA-treated and DHEA þ HFD-treated mice. The number of large antral follicles (per ovary, diameter .311 lm) did not differ between HFD (0.71 6 0.36) and control (0.33 6 0.21) mice, but was significantly increased in DHEA (3.63 6 0.50) and DHEA þ HFD mice (4.00 6 0.66) compared with controls (P , 0.01; Fig. 1C ). In addition, DHEA þ HFD mice contained significantly more large antral follicles than HFD mice (P , 0.01). No obvious difference in the area of the largest follicle was found between HFD (0.07 6 0.04 mm 2 ) and control (0.06 6 0.01 mm 2 ) mice. However, the area of the largest follicle was markedly greater in DHEA (0.13 6 0.08 mm 2 ) and DHEA þ HFD (0.15 6 0.12 mm 2 ) mice than in controls (P , 0.05; data not shown). Moreover, the number of corpora lutea was similar in HFD and control mice, but was significantly lower in DHEA and DHEA þ HFD mice than in control and HFD mice (Fig. 1D) . Collectively, HFD did not affect the reproductive features of DHEA-induced mice. Similar to DHEA mice, DHEA þ HFD mice exhibit reproductive disorders, including acyclicity and polycystic ovaries.
Serum Testosterone Levels
Hyperandrogenism is the most common feature of PCOS. The serum testosterone concentrations were thus measured. There was a marked increase in serum testosterone levels in HFD, DHEA, and DHEA þ HFD mice compared with controls (P , 0.01; Fig. 1E ), indicating hyperandrogenism in these mice. Testosterone levels were significantly higher in DHEA þ HFD mice than in HFD mice (P , 0.01). No significant difference was found between DHEA and DHEA þ HFD groups. Moreover, hyperandrogenism was also clearly observed in DHEA and DHEA þ HFD mice when animals were killed right after the treatments for 20 days without any further evaluation of the metabolic features in another experiment (data not shown). These results suggest that treatment of DHEA causes hyperandrogenism in the mice. A HFD induces an increase in serum testosterone levels, but it does not worsen hyperandrogenism in DHEA mice.
Body Weight Study
Body weight of the mice was similar before the treatments. From Days 5 to 20 of the treatments, the HFD and DHEA þ HFD mice exhibited significantly more weight gain than control and DHEA mice (P , 0.01), as illustrated in Figure 2A . These data suggest that the significant body weight gain in DHEA þ HFD mice is caused by HFD treatment.
Body Fat, Lean, and Intra-Abdominal Fat Mass
To determine the effect of the treatments on body fat and lean mass in vivo, body composition analysis was performed in all the mice. The ratio of lean mass to body weight was similar among the four groups of mice (data not shown). However, the ratio of total body fat to body weight was significantly higher in HFD mice than in controls (P , 0.05), suggesting that HFD induced fat accumulation in the mice (Fig. 2B) . In contrast, the ratio of fat to body weight was significantly lower in DHEA mice than in controls (P , 0.05), indicating the downregulation of fat mass by DHEA treatment alone in vivo. The fat to body weight ratio of DHEA þ HFD mice was also significantly higher than that of DHEA mice (P , 0.05) but was similar to controls, which may be due to the opposing effects of HFD and DHEA on fat mass accumulation. Likewise, the ratio of intra-abdominal fat to body weight was markedly higher in HFD mice than in control (P , 0.01) and DHEA þ HFD (P , 0.01) mice (Fig. 2C) , suggesting the increased distribution of fat in the abdomen by HFD. In contrast, the intra-abdominal fat mass was significantly reduced in DHEA mice compared with controls (P , 0.01). Consistent with the total body fat mass, the intra-abdominal fat to body 
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weight ratio did not differ between DHEA þ HFD and control mice but was significantly higher in DHEA þ HFD than in DHEA mice (P , 0.01). Results from two-way ANOVA showed the marked interaction between DHEA and HFD that affected intra-abdominal fat mass in DHEA þ HFD mice (P , 0.01). Collectively, the treatment of HFD increased, whereas DHEA reduced, the total and abdominal fat mass in the mice. The combined DHEA and HFD treatment displayed an interactive effect on the total and intra-abdominal fat mass in the animals. 
HFD INDUCES METABOLIC FEATURES IN PCOS MICE
Serum Cholesterol and TG Levels
Serum total cholesterol and TG levels were determined. The mice treated with HFD and DHEA þ HFD exhibited significantly higher serum cholesterol levels than control mice (P , 0.01; Fig. 2D ). No apparent difference was observed between control and DHEA mice. However, cholesterol levels were markedly higher in DHEA þ HFD than in DHEA mice (P , 0.01), suggesting that the elevated serum cholesterol levels in DHEA þ HFD mice were caused by HFD. Serum TG concentrations had a trend to be reduced in HFD, DHEA, and DHEA þ HFD mice compared with controls (Fig. 2E ).
OGTT and ITT Experiments
To investigate the effects of the treatments on glucose tolerance of the mice, OGTT was performed. Fasting glucose levels were similar among the groups. The DHEA mice displayed a response to glucose in a pattern similar to that of control mice. Treatments of HFD and DHEA þ HFD resulted in markedly increased serum glucose levels at 30 and 60 min after administration of glucose compared with controls (Fig. 2F ). In addition, statistical analysis revealed a significant elevation in 0-to 120-min AUC value in HFDtreated (P , 0.05) and DHEA þ HFD-treated (P , 0.01) mice (Fig. 2G ) compared with controls, suggesting impaired glucose tolerance in these two groups of animals. No significant difference was found between DHEA and control mice. Serum glucose levels were also measured at the fed state. No apparent difference was observed among the four groups of mice (data not shown). These results suggest that the impaired glucose tolerance in DHEA þ HFD mice is caused by HFD treatment.
Insulin tolerance test was also performed. Blood glucose levels were corrected for fasting glucose (Fig. 2H) . The corrected serum glucose levels were significantly higher in DHEA and DHEA þ HFD mice than in control and HFD mice at 30 and 60 min after injection (P , 0.01). Correspondingly, the AUC was significantly higher in DHEA þ HFD and DHEA mice than in controls (P , 0.05; Fig. 2I ). In addition, the AUC was markedly higher in DHEA þ HFD than in HFD mice (P , 0.01). These data suggested the impaired insulin sensitivity in DHEA and DHEA þ HFD mice was likely caused by the DHEA treatment.
Effect of the Treatments on the Liver
Liver morphology was similar among the mice, as shown by H&E staining (Fig. 3A) . We next assessed lipid content in the liver. Compared with control and DHEA-treated mice, there was a dramatic increase in hepatic lipid accumulation in both HFD and DHEA þ HFD mice, as revealed by Oil Red O staining (Fig. 3A) . The hepatic cholesterol and TG contents were then analyzed. Hepatic cholesterol content in HFD mice was similar to that in controls. Treatments of HFD and DHEA þ HFD induced a marked increase in hepatic TG content in the mice compared with controls (P , 0.01). The DHEA þ HFD mice also showed significantly higher hepatic cholesterol content than control mice (P , 0.05; Fig. 3B ). Both liver cholesterol and TG contents were similar in DHEA and control mice. These contents were significantly higher in DHEA þ HFD mice than in DHEA mice (P , 0.01; Fig. 3B ). Collectively, these data indicate that hepatic lipid content is increased in DHEA þ HFD mice. The elevated liver TG level in DHEA þ HFD mice is likely caused by the HFD treatment.
To understand the molecular mechanisms underlying the effect of the treatments, we evaluated the expression of genes governing hepatic lipogenesis, fatty acid uptake, fatty acid oxidation, and fat export in the liver of the mice (Fig. 3C) . Data from real-time PCR revealed that the expression of hepatic fatty acid translocase (Cd36/Fat) did not differ between HFD and control mice but was dramatically elevated in DHEA and DHEA þ HFD mice compared with controls, suggesting increased fatty acid uptake in DHEA and DHEA þ HFD mice. Expression of sterol regulatory element binding protein isoform-1 (Srebp-1), a key lipogenic gene, was significantly reduced in HFD, DHEA, and DHEA þ HFD mice compared with controls (P , 0.01), indicating decreased hepatic lipogenesis in these mice. In addition, DHEA þ HFD mice exhibited a marked decrease in Srebp-1 gene expression compared with HFD and DHEA mice (P , 0.01). Expression of Acyl-CoA:diacylglycerol acyltransferase 2 (Dgat2) in HFD mice was comparable with that in controls, but Dgat2 expression was significantly reduced in DHEA and DHEA þ HFD mice compared with control mice (P , 0.01), suggesting decreased TG synthesis in these animals. However, Dgat2 expression was lower in DHEA þ HFD mice than in HFD mice (P , 0.01), indicating that the down-regulation of Dgat2 in DHEA þ HFD mice was caused by the DHEA treatment. Cholesterol homeostasis is maintained by two master transcription factors, Liver X Receptors (LXRs) and SREBP-2, within the cells. Hepatic Lxra gene expression was similar in HFD, DHEA, and control mice, but it was significantly reduced in DHEA þ HFD mice compared with control, HFD, and DHEA mice (P , 0.05), implying the decreased cholesterol efflux from the liver of DHEA þ HFD mice. In addition, two-way ANOVA revealed the significant interaction between DHEA and HFD on Lxra expression in DHEA þ HFD mice (P , 0.01). In contrast, hepatic expression of Lxrb was similar in the four groups of mice (data not shown). The expression of Srebp-2 was significantly reduced in DHEA mice compared with controls (P , 0.01), suggesting the decreased cholesterol synthesis and uptake in DHEA mice. No apparent difference was observed between control and DHEA þ HFD, or between control and HFD mice. Besides, the expression of microsomal triglyceride transfer protein (MTTP), a critical regulator of the assembly and secretion of VLDL, was also examined. No apparent difference was observed among the four groups of mice (data not shown). The expression of Carnitine palmitoyl transferase-1a (Cpt-1a), however, was significantly up-regulated in HFD (P , 0.01) and DHEA þ HFD (P , 0.05) mice compared with controls, suggesting elevated fatty acid oxidation in these mice. Cpt-1a expression was similar between DHEA and control mice. In summary, these data indicate increased fatty acid uptake and decreased TG synthesis in DHEA þ HFD mice, which is possibly due to the DHEA treatment. In contrast, fatty acid oxidation is elevated in DHEA þ HFD mice, which is caused by HFD. The up-regulated liver cholesterol level in DHEA þ HFD mice is likely caused by the decreased cholesterol efflux.
Furthermore, we measured the expression of p-AKT and AKT in the mouse liver. Western blot analysis revealed that there were no apparent differences in p-AKT/AKT between HFD and control mice. A significant increase in the ratio of p-AKT/AKT was observed in DHEA (P , 0.01) and DHEA þ HFD (P , 0.05) mice compared with controls (Fig. 3D) . The ratio of p-AKT/AKT was also significantly higher in DHEA þ HFD mice than in HFD mice (P , 0.05). However, the expression of total AKT also varied in DHEA and DHEA þ HFD mice, suggesting the regulation of total AKT by DHEA in the liver (Fig. 3D) .
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Effect of the Treatments on Abdominal Adipose Tissue
Large adipocytes are associated with IR, and adipocyte dysfunction has been demonstrated in a PCOS mouse model that lacks leptin and insulin receptors in pro-opiomelanocortin neurons (IR/LepR POMC mice) [24] . To evaluate the adipocyte function, we first performed H&E staining of the fat tissue. Histological analysis showed the presence of enlarged adipocytes in HFD, DHEA, and DHEA þ HFD mice (Fig.  4A) . More than 1000 adipocytes were measured in each mouse sample, and then adipocytes were pooled from three mice per group to make the adipocyte size distribution curve. The number of enlarged adipocytes was increased in HFD, DHEA, and DHEA þ HFD mice compared with controls (Fig. 4B) , reflected by the right shift of the distribution curve (statistical analysis not done). Accordingly, the mean adipocyte size was also significantly up-regulated in HFD, DHEA, and DHEA þ HFD mice compared with controls (P , 0.01; Fig. 4C ). In addition, the adipocyte size was markedly larger in HFD than in DHEA þ HFD mice (P , 0.01) and was larger in DHEA þ HFD than in DHEA mice (P , 0.01; Fig. 4C ). Macrophages were identified by immunoreactivity with F4/80. Macrophage infiltration of white adipose tissue has been implicated in the metabolic complications of obesity, and white adipose tissue macrophages usually form crownlike structures around individual adipocytes [25] . Immunohistochemical analysis of adipose tissue with anti-F4/80 antibody revealed increased number of crownlike structures in HFD, DHEA, and DHEA þ HFD mice compared with controls (Fig. 4D) , suggesting elevated macrophage infiltration in these mice. No apparent difference in staining was found among HFD, DHEA, and DHEA þ HFD mice.
Effect of the Treatments on Skeletal Muscle
To evaluate insulin sensitivity in the skeletal muscle, we measured the expression of p-AKT and AKT. No apparent difference was observed between HFD and control mice. However, the p-AKT/AKT ratio in the skeletal muscle was significantly reduced in DHEA and DHEA þ HFD mice compared with controls (P , 0.01; Fig. 4E ), suggesting IR in the skeletal muscle of these two groups of mice. These data indicate that the impaired insulin sensitivity in the skeletal muscle of DHEA þ HFD mice is caused by the treatment of DHEA.
DISCUSSION
In the present study, we show that treatment with a 60% HFD induces obesity, glucose intolerance, dyslipidemia, and hepatic steatosis in DHEA-induced PCOS mice with the C57BL/6 background. The treatment of HFD does not affect the reproductive characteristics of DHEA mice.
Since PCOS was initially described in 1935, a number of methods have been applied to generate rodent models of this syndrome, including prenatal and postnatal treatment with androgens, postnatal treatment with estrogens, aromatase inhibitors, etc. [26] [27] [28] [29] . Among these animal models, there are fewer models developed in mice than in rats. However, a variety of gene knockout, transgenic, and conditional gene/ tissue knockout mice that are widely used in other fields should have an advantage over rats and other animal species to address the functionality of specific genes in the pathogenesis of PCOS. Dehydroepiandrosterone is the most abundant steroid hormone in the circulation. It was initially used to induce polycystic ovaries in rats [8] and has been used to induce a PCOS mouse model for almost a decade [14] . In addition, many genetically modified rodent models of PCOS, such as leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice, have suggested a crucial role for energy imbalance in the pathology of this syndrome. Female C57BL/6 mice on the 24% fat diet for 16 wk are resistant to developing obesity and do not manifest diminished fertility associated with HFD [30] . Differently, the mice on a mixed CD1/129SvJ/C57BL6 genetic background fed the 60% fat diet for 12 wk are obese and infertile because of the impairment of ovulation [15] . Given the possible effect of an HFD on reproductive and metabolic pathologies, we therefore treated prepubertal female C57BL/6 mice with DHEA on a 60% HFD.
Similar to DHEA treatment alone, the combined DHEA and HFD treatment induced disturbed cyclicity, multicystic ovaries, and hyperandrogenism in the mice. The HFD-treated mice did not exhibit multicystic ovaries. The phenomenon observed in DHEA þ HFD mice was therefore caused by the effects of DHEA and HFD. Recently, Wu et al. [31] have shown a significant increase in testosterone concentration in dietinduced obese mice. In our study, HFD treatment induced an increase in serum testosterone levels compared with controls, and its potential origin is unclear. In addition, it is also worthy to note that apparent corpus luteal hemorrhage was observed in the ovaries of DHEA and DHEA þ HFD mice, but rarely in those of control and HFD mice (data not shown). The underlying mechanisms remain unknown.
We next evaluated the metabolic features of the mice. It has been reported that about 50% of women with PCOS are obese [32, 33] . Obesity, particularly the abdominal phenotype, is closely associated with infertility, hyperandrogenemia, IR, and hyperinsulinemia in women with PCOS. In the present study, body weight did not differ between DHEA and control mice, which is consistent with previous reports in the context of BALB/c [10] . Increased weight gain was reported in DHEAtreated C57BL/6 mice by Dowling et al. [13] . These conflicting results might be accounted for by differences in environmental factors, such as diet. In contrast, DHEA þ HFD treatment induced significant weight gain compared with control mice, providing the first index of the metabolic derangements in DHEA þ HFD-treated animals. As expected, HFD caused a marked increase in fat mass. The DHEA-treated mice on a 60% HFD, however, appear to be protected from obesity. Androgens can increase visceral fat mass in women. Studies on the animal models and women, however, have also shown that DHEA supplementation reduces fat mass gain and obesity, likely via conversion of DHEA to estrogens [34, 35] . The exact mechanisms underlying the role of DHEA in obesity here is unclear.
Results from OGTT and ITT experiments indicated impaired glucose tolerance and IR in DHEA þ HFD mice. It is known that AKT is a key mediator of the metabolic action of insulin and the p-AKT/AKT ratio is used to evaluate the insulin sensitivity of tissues. The decreased p-AKT/AKT ratio in the skeletal muscle of DHEA þ HFD mice thus suggested resistance to insulin's metabolic actions in the skeletal muscle of DHEA þ HFD mice. In addition, the enlarged adipocytes and inflammation in adipose tissue may also contribute to the IR observed in DHEA þ HFD mice. Indeed, inflammation in adipose tissue is one mechanism proposed to be involved in the development of IR [36] . Enlarged adipocytes are not necessarily correlated with increased abdominal adipose tissue, but they are strongly associated with IR [5] . The p-AKT/AKT ratio should be a good indicator of insulin sensitivity in adipose tissue. However, attempts to measure p-AKT/AKT levels in adipose tissue are limited by the small amount of tissues collected in the present study. Differently, HFD-treated mice LAI ET AL. exhibited impaired glucose tolerance but normal insulin sensitivity, suggesting the impaired insulin secretion that produces the poor glucose tolerance in these mice. The DHEA-treated mice displayed normal responses to glucose stimulation but impaired insulin sensitivity. Impaired glucose tolerance has been reported in DHEA-treated C57BL/6 mice by Dowling et al. [13] , which may be partly attributed to the increased weight gain at the end of the treatment. In contrast, there was no difference in weight gain between DHEA and control mice in the present study. Sander et al. [10] have shown IR in a DHEA-induced PCOS mouse model in the BALB/c background. Our data thus confirmed the effect of DHEA on inducing IR in the mice. In women, DHEA also contributes to IR [37] . Metformin, an insulin sensitizer widely used in the treatment of type 2 diabetes, has been administered to PCOS patients to improve insulin sensitivity [38] .
Dyslipidemia is common in women with PCOS [39] . Significantly elevated serum cholesterol and TG levels are present in most, if not all, PCOS patients [40, 41] . In the present study, treatment of DHEA þ HFD induced markedly elevated serum cholesterol levels in the mice. Slightly reduced serum TG levels were found in HFD, DHEA, and DHEA þ HFD mice compared with controls. Decreased serum TG has been reported in rats fed a 51% HFD for 24 wk [42] , and the underlying mechanisms are not known. In the liver, apparent hepatic steatosis was observed in DHEA þ HFD-treated rather than DHEA-treated mice. Analysis of the genes revealed the increased hepatic fat uptake, reduced lipogenesis, increased fatty acid oxidation, and decreased cholesterol efflux in DHEA þ HFD mice (see Supplemental  Fig. S1 , available online at www.biolreprod.org). The evident hepatic steatosis in DHEA þ HFD mice is thus the consequence of the imbalanced fat uptake, synthesis, oxidation, and exportation in the liver. Furthermore, activation of AKT is known to promote hepatic lipogenesis, which depends on SREBP-1c or mammalian target of rapamycin complex 1 (mTORC1) signaling. We observed activation of AKT in the liver of DHEA þ HFD mice. However, the expression of its downstream molecule SREBP-1 was decreased. It is thus likely that activation of AKT in the liver of DHEA þ HFD mice contributes to the robust lipid accumulation in DHEA þ HFD mice via an SREBP-1-independent mechanism. Women with PCOS also had a higher prevalence of hepatic steatosis [7, 43] . In obese adolescent girls with PCOS, fatty liver is associated with increasing abdominal adiposity, worsening insulin sensitivity, and dyslipoproteinemia [44] . But the exact mechanisms by which PCOS patients have an increased risk of developing hepatic steatosis remain unknown. Hogg et al. [45] have shown that maternal testosterone propionate exposure resulted in the occurrence of hepatic steatosis and alterations in hepatic metabolic gene expression in adult sheep. However, the presence of hepatic steatosis has not been reported in any PCOS mouse models. Therefore, the combined DHEA and HFD treatment can serve as a means for investigating the mechanisms underlying the high prevalence of hepatic steatosis in women with PCOS.
In summary, we present here that a 60% HFD treatment induces significant metabolic disorders in DHEA-treated C57BL/ 6 mice. The similarities and dissimilarities among HFD-treated, DHEA-treated, and DHEA þ HFD-treated mice versus controls are summarized in Table 2 . The combined DHEA and HFD treatment can therefore serve as a means for studying the pathogenesis of metabolic derangements of PCOS at a young age, particularly for the study of the mechanisms underlying the high prevalence of hepatic steatosis in women with PCOS. Additionally, our data also strongly implicate that early exposure to excess lipids during prepuberty may increase the risk for PCOS, especially the metabolic disorders of this syndrome. LAI ET AL.
